Search results for "endothelin"

showing 10 items of 93 documents

Changes of neurohumoral parameters and endothelin-1 in response to exercise in patients with mild to moderate congestive heart failure

1998

Plasma endothelin levels are increased in patients with moderate and severe CHF. Conflicting data exist about the endothelin-1 (ET) level in patients with mild to moderate CHF and the effect of maximal exercise on plasma ET levels.We determined the plasma levels of ET and various neurohumoral parameters in 93 patients with CHF in functional class II and III of the NYHA classification at rest and after maximal bicycle exercise. Baseline ET level was increased compared to an age-matched healthy volunteer group (6.95+/-0.31 vs 3.29+/-0.17 pg/ml, mean+/-S.E.M., P0.05), without significant differences between NYHA class II and III patients. Maximal exercise did not increase the ET level. In cont…

Malemedicine.medical_specialtyHeart diseaseneurohumoral activationheart failurePeptide hormonePLASMA ENDOTHELINInternal medicinemedicineHumanscardiovascular diseasesExercise physiologyExerciseAgedNeurotransmitter AgentsEndothelin-1BLOOD-FLOWbusiness.industryBlood flowMiddle Agedmedicine.diseaseEndothelin 1Pathophysiologyexercise capacityEndocrinologyHeart failureExercise TestCardiologycardiovascular systemFemaleCardiology and Cardiovascular MedicineEndothelin receptorbusinessendothelin
researchProduct

Endothelin-1-induced potentiation of adrenergic responses in the rabbit pulmonary artery: role of thromboxane A(2).

2001

Abstract To examine whether low concentrations of endothelin-1 potentiate the vasocontrictor response to adrenergic stimulation, we recorded the isometric response of rings of rabbit pulmonary artery to electrical stimulation and noradrenaline. Endothelin-1 (10 −10 M) potentiated the contractions induced by electrical stimulation and noradrenaline. The endothelin ET B receptor antagonist (2,6-dimethylpiperidinecarbonyl-γ-methyl-Leu- N in -[Methoxycarbonyl]- d -Trp- d -Nle) (BQ-788, 10 −6 M), but not the endothelin ET A receptor antagonist cyclo( d -Asp-Pro- d -Val-Leu- d -TRP) (BQ-123, 10 −6 M), inhibited the potentiating effects of endothelin-1. Pretreatment with the cyclooxygenase inhibit…

Malemedicine.medical_specialtyNifedipineThromboxanemedicine.drug_classAdrenergicPulmonary ArteryThromboxane A2chemistry.chemical_compoundNorepinephrineThromboxane A2PiperidinesInternal medicinemedicineAnimalsVasoconstrictor AgentsAntihypertensive AgentsPharmacologybiologyDose-Response Relationship DrugEndothelin-1Receptors EndothelinReceptor antagonistCalcium Channel BlockersEndothelin 1Receptor Endothelin BElectric StimulationEndocrinologychemistryVasoconstrictionbiology.proteinCyclooxygenaseThromboxane-A synthaseRabbitsEndothelin receptorOligopeptidesEuropean journal of pharmacology
researchProduct

Chronic Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction, Oxidative Stress and a Marked Increase in Vascular Endothelin-1 Express…

2011

Aims Isosorbide-5-mononitrate (ISMN) is one of the most frequently used compounds in the treatment of coronary artery disease predominantly in the USA. However, ISMN was reported to induce endothelial dysfunction, which was corrected by vitamin C pointing to a crucial role of reactive oxygen species (ROS) in causing this phenomenon. We sought to elucidate the mechanism how ISMN causes endothelial dysfunction and oxidative stress in vascular tissue. Methods and results Male Wistar rats ( n = 69 in total) were treated with ISMN (75 mg/kg/day) or placebo for 7 days. Endothelin (ET) expression was determined by immunohistochemistry in aortic sections. Isosorbide-5-mononitrate infusion caused si…

Malemedicine.medical_specialtyNitric Oxide Synthase Type IIIIsosorbide DinitratePharmacologymedicine.disease_causeBiochemistryMicechemistry.chemical_compoundSuperoxidesEnosInternal medicinePhysiology (medical)medicineAnimalsNitric Oxide DonorsEnzyme InhibitorsRats WistarEndothelial dysfunctionCyclic GMPAortaMice KnockoutNADPH oxidaseEndothelin-1biologybusiness.industryNADPH Oxidasesmedicine.diseasebiology.organism_classificationEndothelin 1BosentanRatsNitric oxide synthaseEndothelial stem cellOxidative StressNG-Nitroarginine Methyl EsterEndocrinologychemistryApocyninbiology.proteinEndothelium VascularCardiology and Cardiovascular MedicineEndothelin receptorbusinessOxidative stressSignal Transductionmedicine.drugFree Radical Biology and Medicine
researchProduct

Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats

1996

The present study evaluates the effects of pre-hepatic portal hypertension, induced in rats by partial portal vein ligation, on the responsiveness of rostral (proximal) and caudal (distal) rings from the mesenteric vein. The anatomical origin of the sample influenced the response to vasoconstrictors in sham-operated animals, and this pattern of reactivity was specifically modified in portal-ligated rats. In veins from sham-operated rats, contraction induced by a submaximal concentration of KCl (60 mM) was greater in proximal than in distal rings. Vasopressin and 5-hydroxytryptamine contracted mainly distal rings, methoxamine showed a greater effect on proximal rings, and endothelin-1 and an…

Malemedicine.medical_specialtyVasopressinContraction (grammar)VasopressinsPropranololIliac VeinIn Vitro TechniquesMuscle Smooth VascularMesenteric VeinMethoxaminePotassium ChlorideNitric oxideRats Sprague-Dawleychemistry.chemical_compoundMesenteric VeinsInternal medicineHypertension PortalmedicineAnimalsVasoconstrictor AgentsPharmacologyEndothelin-1business.industryGeneral Medicinemedicine.diseaseRatsAtropineEndocrinologychemistrycardiovascular systemPortal hypertensionbusinessmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Does plasma endothelin during thrombolysis depend on infarct size? A pilot study

1995

Dear Sir, Endothelin is a recently discovered endotheliumderived vasoconstrictive peptide [1]. Endothelin's actions are altered in various models of cardiac injury [2]. Furthermore, it has been shown that endothelin is increased during reperfusion [2]. Studies have shown a significant increase in endothelin-1 (ET-1) in the early phases of acute myocardial infarction (AMI) and percutaneous transluminal coronary angioplasty (PTCA) [3-8]. In addition, a significant inverse relation between ventricular function and plasma ET-1 has been shown [6]. These data suggest that ET-1 may provide a marker of endothelial injury in the early phases of coronary ischemia or may even contribute to alterations…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionInfarctionPilot ProjectsInternal medicinemedicineHumansThrombolytic TherapyPharmacology (medical)cardiovascular diseasesMyocardial infarctionAgedPharmacologybusiness.industryEndothelinsGeneral MedicineCoronary ischemiaThrombolysisPlasma levelsMiddle Agedmedicine.diseaseInfarct sizeEndothelin 1Tissue Plasminogen Activatorcardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEndothelin receptorCardiovascular Drugs and Therapy
researchProduct

Antihypertensive effects of lactoferrin hydrolyzates: Inhibition of angiotensin- and endothelin-converting enzymes

2013

The potential of bovine lactoferrin (LF) as a source of antihypertensive peptides acting on the renin-angiotensin system (RAS) and the endothelin (ET) system as dual vasopeptidase inhibitors has been examined. For this purpose enzymatic LF hydrolyzates (LFHs) were generated by trypsin and proteinase K digestions. Permeate fractions with molecular masses lower than 3 kDa (LFH <3 kDa) were orally administered to spontaneously hypertensive rats (SHRs). Although both LFHs <3 kDa showed in vitro angiotensin I-converting enzyme (ACE)-inhibitory activity, only proteinase K LFH <3 kDa exerted an in vivo antihypertensive effect. The proteinase K LFH <3 kDa and a previously characterized pepsin LFH <…

Malemedicine.medical_treatmentLactoferrin hydrolyzatesMolecular Sequence DataPeptideAngiotensin-Converting Enzyme InhibitorsBlood PressureIn Vitro TechniquesPeptidyl-Dipeptidase AECE-dependent vasoconstrictionAnalytical ChemistryIn vivoRats Inbred SHRmedicineVasopeptidase InhibitorsAnimalsAmino Acid SequenceAntihypertensive Agentschemistry.chemical_classificationProteasebiologyLactoferrinEndothelinsHydrolysisGeneral MedicineVasopeptidase inhibitorsRenin–angiotensin systemProteinase KTrypsinEndothelin systemRatsLactoferrinEnzymeCarotid ArteriesBiochemistrychemistryVasoconstrictionHypertensionbiology.proteinCattleRabbitsFood Sciencemedicine.drugACE-dependent vasoconstriction
researchProduct

New molecular targets in bone metastases.

2010

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results fr…

Oncologymedicine.hormonemedicine.medical_specialtyPathologyCathepsin KProto-Oncogene Proteins pp60(c-src)Antineoplastic AgentsBone NeoplasmsBone NeoplasmAntibodies Monoclonal HumanizedEndothelinMetastasisAntineoplastic AgentEndothelinsBone metastases; Molecular targets; Animals; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bone Neoplasms; Cathepsin K; Denosumab; Endothelins; Humans; Proto-Oncogene Proteins pp60(c-src); RANK Ligand; Medicine (all); Oncology; Radiology Nuclear Medicine and ImagingInternal medicineMedicineAnimalsHumansRadiology Nuclear Medicine and imagingMolecular targetbiologyAnimalbusiness.industryMedicine (all)EndothelinsRANK LigandCancerBone metastasisAntibodies MonoclonalGeneral Medicinemedicine.diseaseClinical trialBone metastaseDenosumabOncologyRANKLCancer cellbiology.proteinDenosumabbusinessHumanmedicine.drugCancer treatment reviews
researchProduct

Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy:

2021

n/a.

Oncologymedicine.medical_specialtyMEDLINEeGFR declineType 2 diabetesEgfr declineendothelin receptor antagonistlaw.inventionRandomized controlled triallawInternal medicinePost-hoc analysismedicinebusiness.industryEndothelin receptor antagonistAtrasentan22/2 OA procedureGeneral Medicinemedicine.diseaseClinical trialNephrologyrandomized controlled trialtype 2 diabetesbusinesschronic kidney diseasemedicine.drugJournal of the American Society of Nephrology
researchProduct

Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease

2001

BACKGROUNDHirschsprung disease (HSCR) is a frequent congenital disorder with an incidence of 1 in 5000 live births, characterised by the absence of parasympathetic intramural ganglion cells in the hindgut resulting in intestinal obstruction in neonates and severe constipation in infants and adults. Intestinal neuronal dysplasia (IND) shares clinical features with HSCR but the submucosal parasympathetic plexus is affected. IND has been proposed as one of the most frequent causes of chronic constipation and is often associated with HSCR.METHODSWe examined 29 patients diagnosed with sporadic HSCR, 20 patients with IND, and 12 patients with mixed HSCR/IND for mutations in the coding regions of …

Pathologymedicine.medical_specialtyGlial Cell Line-Derived Neurotrophic Factor ReceptorsHirschsprung diseaseMUTATION ANALYSISNerve Tissue ProteinsTYROSINE KINASEEDNRBArticleExonGermline mutationProto-Oncogene ProteinsNEUROTROPHIC FACTOR GDNFmedicineGlial cell line-derived neurotrophic factorDrosophila ProteinsHumansGlial Cell Line-Derived Neurotrophic FactorNerve Growth FactorsAlleleintestinal neuronal dysplasiaAllelesPolymorphism Single-Stranded ConformationalIntestinal neuronal dysplasiabiologyReceptors EndothelinSHAH-WAARDENBURG SYNDROMEProto-Oncogene Proteins c-retENDOTHELIN-B-RECEPTORMULTIGENIC INHERITANCEGastroenterologyReceptor Protein-Tyrosine KinasesSequence Analysis DNAGERMLINE MUTATIONSbiochemical phenomena metabolism and nutritionPROTOONCOGENEmedicine.diseasePHENOTYPIC-EXPRESSIONGDNFPedigreeProto-Oncogene Proteins c-retDysplasiaCase-Control StudiesMutationbiology.proteinLIGANDRETCongenital disorderEDN3
researchProduct

Isolation of endothelin A receptor from bovine lungs.

1995

We isolated endothelin receptor A (ET A ) from bovine lungs in a single-step purification procedure using antibodies raised against synthetic peptides that correspond to extra- and intracellular domains of the rat bradykinin receptor. Two receptor species of 55 and 35 kDa were isolated and subjected to N-terminal microsequencing. The difference between the observed and expected molecular weight species suggests that bovine ET A receptor is glycosylated.

PharmacologyGlycosylationReceptors EndothelinBiologyIn vitroRatsMolecular Weightchemistry.chemical_compoundBiochemistryAffinity chromatographychemistrybiology.proteinAnimalsCattleRabbitsAntibodyBradykinin receptorCardiology and Cardiovascular MedicineEndothelin receptorReceptorLungIntracellularJournal of cardiovascular pharmacology
researchProduct